Home›Research›Compare›Retatrutide vs Tesamorelin
Peptide ComparisonRetatrutide vs Tesamorelin
Retatrutide
LY3437943
Half-life: ~6 days
98 providers listed
Tesamorelin
Egrifta
Half-life: 26–38 minutes
242 providers listed
Retatrutide and Tesamorelin target different goals — Retatrutide for profound weight loss, Tesamorelin for FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta / Egrifta SV). They're compared here for reference, not as direct substitutes.
Retatrutide
Evidence
Half-life
~6 days
Tesamorelin
Evidence
Half-life
26–38 minutes
Retatrutide and Tesamorelin target different goals — Retatrutide for Metabolic, Tesamorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Retatrutide
Tesamorelin
Retatrutide
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Beyond weight loss: multisystem benefits of obesity medications.
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
+9 more
Tesamorelin
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with exce…
Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 RCTs
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant…
+3 more
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
About Tesamorelin
Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Retatrutide
Class-based (investigational)
Tesamorelin
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceRetatrutide
Tesamorelin
Where to source these peptides
Retatrutide
98 listed
Browse directory →
Providers offeringTesamorelin
242 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Retatrutide vs Tesamorelin — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/retatrutide/tesamorelin